Pharmacoepidemiological Study of the Impact of Roactemra Treatment on Fatigue in Rheumatoid Arthritis Patients in a Real Life Setting

Trial Profile

Pharmacoepidemiological Study of the Impact of Roactemra Treatment on Fatigue in Rheumatoid Arthritis Patients in a Real Life Setting

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms PEPS
  • Sponsors Roche
  • Most Recent Events

    • 17 Jun 2017 Results of pooled analysis (n=1494) of three observational studies (PEPS, Spare-1 and Act-solo), presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 07 Sep 2015 Results published in the Clinical and Experimental Rheumatology.
    • 16 Mar 2012 Actual number of patients changed from 387 to 719 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top